TEMAZEPAM

Search structure
Trade Names:
Synonyms:
Status: Approved (1981)
Entry Type: Small molecule
Molecule Category: Parent
ATC: N05CD07
UNII: CHB1QD2QSS

Structure
InChI Key SEQDDYPDSLOBDC-UHFFFAOYSA-N
Smile CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21
InChI
InChI=1S/C16H13ClN2O2/c1-19-13-8-7-11(17)9-12(13)14(18-15(20)16(19)21)10-5-3-2-4-6-10/h2-9,15,20H,1H3

Physicochemical Descriptors

Property Name Value
Molecular Formula C16H13ClN2O2
Molecular Weight 300.75
AlogP 2.47
Hydrogen Bond Acceptor 3.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 1.0
Polar Surface Area 52.9
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 21.0

Experimental and Estimated Properties

Property Name Value Unit Method
log P (octanol-water) 2.19 - EXP
Henry's Law Constant 1.13E-08 atm-m3/mole EST
Atmospheric OH Rate Constant 1.44E-11 cm3/molecule-sec EST
Melting Point 119-121 deg C EXP
Water Solubility 164 mg/L EST
Vapor Pressure 2.14E-11 mm Hg EST

Pharmacology

Action Mechanism of Action Reference
POSITIVE ALLOSTERIC MODULATOR GABA-A receptor; anion channel positive allosteric modulator FDA Wikipedia Wikipedia

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Pulmonary Disease, Chronic Obstructive 3 D029424 ClinicalTrials
Schizophrenia 3 D012559 ClinicalTrials
Anxiety 3 D001007 ClinicalTrials
Dementia 3 D003704 ClinicalTrials
Depressive Disorder 3 D003866 ClinicalTrials

Related Entries

MCS

Scaffolds

Side Effects from Label

Side effects Relative Frequency (%) Labels
Nervous system disorders Headache
Nervous system disorders Headache 9.1
Nervous system disorders Somnolence 9.1
Nervous system disorders Headache 8.5
Psychiatric disorders Nervousness
Psychiatric disorders Nervousness 8.2
Psychiatric disorders Tension
Psychiatric disorders Tension 8.2
Nervous system disorders Somnolence
Nervous system disorders Somnolence 5.6
General disorders and administration site conditions Asthenia 4.8
General disorders and administration site conditions Fatigue 4.8
General disorders and administration site conditions Asthenia
General disorders and administration site conditions Asthenia 4.7
General disorders and administration site conditions Fatigue
General disorders and administration site conditions Fatigue 4.7
Psychiatric disorders Nervousness 4.6
Psychiatric disorders Tension 4.6
Cardiac disorders Dizziness 4.5
General disorders and administration site conditions Lethargy 4.5
Gastrointestinal disorders Nausea
Gastrointestinal disorders Nausea 3.8
General disorders and administration site conditions Lethargy
General disorders and administration site conditions Lethargy 3.4
Cardiac disorders Dizziness
Cardiac disorders Dizziness 3.3
Gastrointestinal disorders Nausea 3.1
General disorders and administration site conditions Hangover 2.5
Gastrointestinal disorders Dry mouth
Gastrointestinal disorders Dry mouth 2.2
Psychiatric disorders Anxiety 2.0
Gastrointestinal disorders Abdominal discomfort
Gastrointestinal disorders Abdominal discomfort 1.9
Psychiatric disorders Depression
Psychiatric disorders Depression 1.8
Psychiatric disorders Depression 1.7
Gastrointestinal disorders Diarrhoea 1.7
Gastrointestinal disorders Dry mouth 1.7
Psychiatric disorders Nightmare
Psychiatric disorders Nightmare 1.7
Gastrointestinal disorders Abdominal discomfort 1.5
Psychiatric disorders Anxiety
Psychiatric disorders Anxiety 1.5
Psychiatric disorders Euphoric mood 1.5
General disorders and administration site conditions Asthenia 1.4
Nervous system disorders Confusional state 1.3
General disorders and administration site conditions Feeling abnormal 1.3
Eye disorders Vision blurred
Eye disorders Vision blurred 1.3
Psychiatric disorders Nightmare 1.2
Ear and labyrinth disorders Vertigo 1.2
Gastrointestinal disorders Diarrhoea
Gastrointestinal disorders Diarrhoea 1.1
General disorders and administration site conditions Hangover
General disorders and administration site conditions Hangover 1.1
General disorders and administration site conditions Asthenia
General disorders and administration site conditions Asthenia 0.9
Ear and labyrinth disorders Vertigo
Ear and labyrinth disorders Vertigo 0.8
Nervous system disorders Confusional state
Nervous system disorders Confusional state 0.5
General disorders and administration site conditions Feeling abnormal
General disorders and administration site conditions Feeling abnormal 0.5
Psychiatric disorders Euphoric mood
Psychiatric disorders Euphoric mood 0.4

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Psychiatric disorders
20.91
General disorders and administration site conditions
19.62
Nervous system disorders
16.57
Injury, poisoning and procedural complications
9.56
Gastrointestinal disorders
4.01
Skin and subcutaneous tissue disorders
3.25
Cardiac disorders
3.07
Vascular disorders
2.84
Respiratory, thoracic and mediastinal disorders
2.8
Musculoskeletal and connective tissue disorders
2.66
Investigations
2.18
Product issues
2.07

Environmental Impact

Environmental Impact Map
Countries
Austria
Bulgaria
Croatia
Czech Republic
Germany
Hungary
Romania
Serbia
Slovak Republic
United Kingdom
USA

Cross References

Resources Reference
CAS NUMBER 846-50-4
ChEBI 9435
ChEMBL CHEMBL967
DrugBank DB00231
DrugCentral 2585
EPA CompTox DTXSID8021309
FDA SRS CHB1QD2QSS
Human Metabolome Database HMDB0014376
Guide to Pharmacology 7300
KEGG C07125
PharmGKB PA451608
PubChem 5391
SureChEMBL SCHEMBL29463
ZINC ZINC00896634
CONTENTS